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VaRiability in HybRid dRug aVailability and PRicing in EuRoPE
Flostrand S.J.A.1, Lor S.1, Hughes A.L.H.2
1IMS Consulting Group, La Défense Cedex, France, 2IMS Consulting Group, London, UK
Objectives: Medicinal products where active substance, strength, form, or 
administration route have been modified differ from generic drugs as bioequiva-
lence cannot be demonstrated. In Europe, these ‘hybrid’ products have a clear 
registration pathway (Directive 2001/83/EC) requiring investment in pre-clinical 
and clinical trials. However; beyond the regulatory pathway, pricing and market 
access remains a national matter and few countries have specific methods to 
evaluate hybrids; both innovative- and generic-like prices may result. This study 
evaluated hybrid price differences and consequences for availability of hybrids 
across Europe. MethOds: Using IMS MIDAS data and the HMA database of regis-
tered drugs, we screened 5,000 products to identify 40 hybrid products which were 
significantly differentiated from the reference product, launched between 2008-
2012 and analysed their prices and availability based on sales achieved, versus the 
reference product within and across 10 European markets. Results: Hybrid prices 
vary widely, but most frequently, generic rules are applied, limiting the interest of 
companies to make hybrids available across European markets. There is wide vari-
ation in availability of hybrids across markets, suggesting a decision not to launch 
in markets where prices are particularly unfavourable. Countries applying fixed 
generic pricing rules appear to have fewer hybrids. Yet where they are launched, 
hybrids are not classified as generics, so uptake is inhibited by non-substitution 
rules and prescribing quotas. cOnclusiOns: The lack of clear evaluation criteria 
and pricing variability within and across countries are barriers to the availability 
of hybrid products to patients in Europe. To the degree that such products bet-
ter meet patient needs versus generic medicines, these barriers reduce patient 
welfare and prescriber choice. In a context where patient-oriented outcomes are 
increasingly seen as important, hybrid drugs have a role to play given their ability 
to improve administration, compliance, convenience and in some cases improve 
safety and efficacy. Consequently, clear rules for hybrid evaluation, pricing and 
access are desirable as they would improve patient care and reduce uncertainty 
for hybrid manufacturers.
PR4
oVERViEw of coVERagE witH EVidEncE dEVEloPmEnt in SwEdEn
Schroeder M.1, Kornfeld A.2, Ben Abdallah I.2, Rémuzat C.2, Toumi M.3
1Creativ-Ceutical, Copenhagen, Denmark, 2Creativ-Ceutical, Paris, France, 3University Claude 
Bernard Lyon 1, Lyon, France
Objectives: Coverage with evidence development (CED) in Sweden has become 
common over the last decade. It is considered as a tool to address uncertainty. The 
objective of this research is to assess from 2005 to 2012 CED in Sweden. MethOds: 
We downloaded available CED from pricing authority (TLV) database, and extracted 
detailed information in an ad hoc grid developed for that purpose. The following 
information was extracted: date of product approval, name, indication, date of CED 
installation, end of CED, type of evidence to be generated, limitation of initial file 
supporting the need of additional evidences. Results: A total of 28 cases were 
retrieved covering 9 main disease areas. Eleven were for orphan drugs and 10 for 
Central nervous system (CNS) disorders including depression anxiety, epilepsy, 
pain, ADHD, schizophrenia, restless syndrome and Parkinson disease. Other were 
classified as follow, 5 for cardiovascular disorders, 3 oncology, 2 diabetes, 2 res-
piratory disorders and 5 others. The main drivers to request CED were weak cost-
effectiveness model (14 cases) driven by uncertainty about utility, patients benefit, 
transition probabilities, model structure etc. The second reason was low relevance 
of clinical evidence for clinical practice (8 cases), followed by long term efficacy 
extrapolation (5 cases) and others mainly related to comparative effectiveness, 
daily dosage, safety, target population, etc. (11 cases). For each CED more than one 
driver could be identified. Requirements were mostly real world evidence genera-
tion. cOnclusiOns: CED in Sweden is likely to be driven more by uncertainty than 
drug prices due to low involvement of oncology, inflammation and other disease 
area where biologics are prescribed. Orphan drugs represent a leading target for CED 
as often little information is available at time of launch. Most CED are not finalised 
to assess the actual CED impact on long term coverage.
RESEaRcH on mEtHodS – PRo/Qol StudiES
Ql1
maPPing tHE ccQ onto EQ-5d ScoRES (im)PoSSiblE?
Boland M.R.S.1, van Boven J.F.2, Rutten-van Mölken M.P.M.H.1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2University of Groningen, 
Groningen, The Netherlands
Objectives: Studies assessing the effectiveness of new Chronic Obstructive 
Pulmonary Disease (COPD) treatments commonly use disease-specific health-
related quality-of-life (HR-QoL) instruments such as the Clinical COPD Questionnaire 
(CCQ). However, for the economic evaluations, utility data is necessary. This study 
aims to develop a model to predict mean utility values for a group of COPD patients 
using CCQ data. MethOds: We combined the data from two trials (RECODE and 
GO-AHEAD) including over 5000 observations with a broad range of disease sever-
ity. Data was randomly split into an estimation and validation sample. The overlap 
between the CCQ and EQ-5D was assessed using principal component and correla-
tion matrix analysis. Different types of models were created with increasing com-
plexity. We analysed the effect of using different observations of the same patients 
as unique observations and performed a sensitivity analysis using different EQ-5D 
value sets to estimate EQ-5D utilities. The external validity was tested with the 
dataset of the MARCH trial. Results: The principal component analyses showed 
a poor correlation of the dimension pain/discomfort with any of the CCQ items and 
the CCQ items cough and produce phlegm did not load onto any EQ-5D dimension. 
The model using ordinary least square with the individual CCQ items as dummy 
variables, controlled for sex, resulted in the best predicted performance. The mean 
procedure specified for implant registries in general. Therefore, the aim of this 
work is to identify quality criteria for the design and development of implant 
registries and to develop a minimal data set. MethOds: The systematic literature 
search was performed in different databases (Pubmed, Medline, the Cochrane 
Library, Scopus, Embase as well as the CRD York database) and different jour-
nals. Results: Ten articles were identified that describe a general implant registry 
design and structure as well as 45 articles about the creation of specific registries. 
Most recommendations for the organization of implant registries could be found 
in the field of arthroplasty. To generalize the results, it can be said, that all regis-
tries have to deliver a minimal data set including prostheses, patient and surgical 
procedure details. The geographical area, length and periodicity of data collection, 
number of patients enrolled, the composition of the team as well as information 
about security and confidentiality of data should be reported. cOnclusiOns: 
Well-structured registries are a cornerstone of the regulatory process of medical 
devices and a major tool for decison makers and managers. However, only a small 
number of papers that describe specific requirements for the construction of an 
implant registry could be identified. With the establishment of clear guidelines, the 
outcomes of the implant registries can be fundamentally improved. This project 
is supported by the German Federal Ministry of Education and Research (BMBF) as 
part of the National Cluster of Excellence‚ Medical Technologies – Medical Valley 
EMN’ (Project grant No. 13EX1013B).
PRicing StudiES
PR1
PRicE diffEREncES tRiggEREd by tHE aVailability of bioSimilaRS in 
dEVEloPEd countRiES
Reinaud F.1, Ando G.2
1IHS, Paris, France, 2IHS, London, UK
Objectives: The goal of this study is to analyse price differences triggered by 
the availability of biosimilars in developed pharmaceutical markets. MethOds: 
1) Market availability of biosimilars in the following markets was studied: Australia, 
Canada, France, Germany, Italy, Spain, UK, Japan and the United States. Biosimilars 
were selected based on their availability in these markets, and 2) Ex-factory price 
differences at launch between biosimilars and their originator counterparts were 
analysed. Results: Price differences between biosimilars and their originator 
counterpart were on average 25%. One exception aside, biosimilars always trigger 
double digit price differences. Given the limited availability of biosimilars, it is too 
soon to say if results will be consistent over time. Nevertheless, the general trend 
shows that large price differences are observed in Canada and the US (at least 
35%) and lower trends in Australia (around 16%). In the top 5 European pharma-
ceutical markets, price differences range between 17% and 30%. In Japan, price 
differences are also high, 29% on average. It should also be highlighted that the 
market entry of biosimilars does not always trigger the price of their originator 
to drop; in rare occasions only are their prices brought into line. cOnclusiOns: 
Owing to the fact that biologic drugs are commonly expensive and with double 
digit price differences between biosimilars and their originator counterpart, the 
market entry of biosimilars should enable governments to generate significant 
savings. Nevertheless, a limited number of biosimilars are at the moment approved 
and in addition to the fact that no legislation is in place in the US, there is no sign 
of improvement in the other countries studied. As a consequence, savings will 
only be achieved if governments incentivise the development of biosimilars as 
well as their use.
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PHaRmacEutical PoliciES, REgulation and EfficiEncy
Maniadakis N.1, Kourlaba G.2, Shen J.3, Holtorf A.P.4, Kalo Z.5
1National School of Public Health, Athens, Greece, 2National and Kapodistrian University of 
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Objectives: In the context of ever increasing demand and expenditure for health 
services it is important to identify policies which may maximise efficiency. Often, 
pharmaceuticals (approximately 20% of total health care expenditure) are a pri-
mary target for achieving efficiencies. This study aims to study the efficiency 
of pharmaceutical control policies. MethOds: Data on pharmaceutical policies 
and markets across 65 countries were collected from the published literature, 
with emphasis on the following domains: pricing, reimbursement, dispensing, 
expenditure and demand control. In each domain, policies were classified and 
through a multiple-country expert survey were graded for the degree of regu-
lation. Countries were clustered according to their policy mix. Principal com-
ponent analysis (PCA) served to group policies into three components: pricing 
policies, reimbursement policies and demand and cost control policies. Regression 
analysis with pharmaceutical expenditure as % of GDP as dependent variable 
was used to analyse the efficiency of policies. Independent variables were life 
expectancy, dependency ratios, mortality rates, GDP per capita and health system 
type. Results: Spearman correlation coefficients indicated that there was no 
statistically significant association between total pharmaceutical expenditure 
as % of GDP and regulation in the coverage, pricing, reimbursement, dispensing 
policy and system type. A statistically significant positive correlation between 
regulation and indirect price and cost controls (0.334, p= 0.028) and demand con-
trols (0.333, p= 0.019) implies that more regulation in these domains is associated 
with higher expenditure. Following the PCA, regulation in demand control policies 
was associated with higher expenditure (0.342, p= 0.025) and the same applies 
for the aggregate of the components (0.314, p= 0.040). In regression analysis the 
coefficients (p-value) were pricing:-0.003(0.950), demand control:0.062(p= 0.067), 
reimbursement: -0.057(0.439), mortality: 0.001(0.414), Life Expectancy: 0.062(0.474), 
elderly ratio: 0.689(0.774), GDP-per-capita: -1.788(0.017). cOnclusiOns: A variety 
of policies were developed recently to control pharmaceuticals. More regulation 
does not appear to increase efficiency or decrease expenditure.
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Outcomes Study Cognitive Functioning-Revised [MOS COG-R]; PHQ-9, Patient Global 
Impression of Severity [PGIS] and Change [PGIC]; SF-36 Health Survey [SF-36], Lam 
Employment Absence and Productivity Scale [LEAPS], Sheehan Disability Scale 
[SDS] and Work Productivity and Activity Impairment: Specific Health Problem 
[WPAI:SHP]. Results: The study population consisted of 855 subjects at baseline 
(418 US and 437 UK), with MDD patients representing 49% of the sample in each 
country; 169 and 153 MDD patients were invited for the follow-up in the US and 
UK, respectively. Internal consistency was high for the total scale and for the four 
proposed subscales (Attention, Retrospective memory, Prospective memory, and 
Planning), with Cronbach’s alpha ranging from 0.81 to 0.96. Convergent validity was 
supported by strong correlations with other measures of cognitive functioning (0.8 
Pearson’s coefficient) and moderate correlations with several construct measures 
known to be associated with cognitive functioning, including health-related quality 
of life, productivity at work, and other functional impairment (Pearson’s coefficients 
ranging from 0.3 to 0.6), and by substantial differences in scores in subgroups known 
to differ in cognitive functioning impairment. The PDQ-D was also responsive to 
changes in depression symptom severity. Confirmatory factor analyses supported 
the scoring of a global scale for perceived cognitive functioning. cOnclusiOns: The 
PDQ-D is a reliable, valid and responsive instrument for assessing MDD patients’ 
perception of deficits related to cognitive functioning.
RESEaRcH PoStER PRESEntationS – SESSion i 
diSEaSE-SPEcific StudiES
indiVidual’S HEaltH – clinical outcomes Studies
PiH1
motHERS’ own milk foR tHE fEEding of PREtERm infantS: a SyStEmatic 
litERatuRE REViEw
Garcia-Stewart S., Mitchell S.A.
Abacus International, Bicester, UK
Objectives: To conduct a systematic review to examine the incremental benefits 
of mothers’ own milk (MM), with or without fortification, compared with donor 
milk (DM) and/or preterm formula (PF) for the nutritional support of preterm 
infants both in the neonatal intensive care unit (NICU) and following hospital dis-
charge. MethOds: English-language studies published post-1990 were identified 
from electronic databases (Medline, EMBASE and Cochrane Library) and confer-
ence proceedings. Eligible studies enrolled infants with mean gestational age less 
than 35 weeks with no restriction on geographical location. Results: Thirty-three 
unique studies met eligibility criteria: United States (n= 12), Canada (n= 2), Australia 
(n= 2), Mexico (n= 1), Israel (n= 2), Europe (n= 13) or multinational (n= 1). There was 
a paucity of both RCT data (n= 7) and studies which reported exclusive use of MM 
feeding (n= 3). In addition, there was considerable heterogeneity between studies 
with regard to study design, duration of follow up and amounts of MM ingested, and 
a robust meta-analysis was therefore not feasible. However, a significant beneficial 
effect for MM over DM and/or PF for the incidence of sepsis, necrotizing enterocolitis 
(NEC) and longer-term neurodevelopment was reported in a number of individual 
studies. With regard to anthropomorphic outcomes of body weight, length and 
head circumference, there was no clear consensus on the effect of feeding regi-
men. Sixteen studies reported the relationship between the dose of MM received 
and outcomes; increased MM dosages in the feeding regimen were associated with 
significantly lower rates of sepsis, NEC, and hospital readmissions, reduced NICU 
costs, and improved neurodevelopment. cOnclusiOns: Exclusive or high-dose 
MM with or without fortification is associated with short- and long-term beneficial 
effects in preterm infants. These results confirm MM to be the optimal nutrition for 
preterm infants and stress the importance of developing comprehensive strategies 
to overcome the challenges of providing MM and improving breastfeeding rates in 
preterm infants in the NICU.
PiH2
utERinE-SPaRing SuRgical tREatmEnt modalitiES in womEn witH 
utERinE fibRoidS: a SyStEmatic REViEw and indiREct tREatmEnt 
comPaRiSon
Panagiotopoulou N.1, Nethra S.1, Karabis A.2, Ahmad G.1, Burls A.3
1Pennine Acute Hospitals NHS Trust, Manchester, UK, 2Mapi – HEOR & Strategic Market Access, 
Houten, The Netherlands, 3City University London, London, UK
Objectives: To evaluate the safety and effectiveness of conservative sur-
gical treatments for uterine fibroids in women who wish to preserve their 
uterus. MethOds: A systematic literature search of electronic databases 
(MEDLINE, EMBASE, CENTRAL) and grey literature up to October 2012 identified 5 
RCTs (436 patients): 2 comparing uterine artery embolization (UAE) with myomec-
tomy (MYO) and 3 comparing UAE with laparoscopic uterine artery occlusion 
(LUAO). Primary outcome measures included patients’ satisfaction, re-intervention 
and ovarian failure rate. Secondary outcomes were clinical failure, hysterectomy 
and complication rates, hospitalization and recovery times, pregnancy rate, preg-
nancy complications and live-birth rate. Standard and network meta-analysis 
were performed on relevant outcomes. Results: Of the three most popular 
uterine-sparing surgical treatments for fibroids, network meta-analysis showed 
that MYO and UAE resulted in higher rates of patient satisfaction and lower rates 
of clinical failure than LUAO in the first year after treatment [OR 2.56, 95%CrI 0.56- 
11.75, P(better)= 11% and 2.7, 95%CrI 1.1- 7.14, P(better)= 1%; 0.29, 95%CrI 0.06- 1.46, 
P(better)= 7% and 0.37, 95%CrI 0.13- 0.93, P(better)= 2% respectively]. Moreover, MYO 
resulted in lower re-intervention and hysterectomy rates than UAE and LUAO [0.08, 
95%CrI 0.02- 0.27, P(better)< 1%, 0.08, 95%CrI 0.01- 0.37 P(better)< 1%); 0.16, 95%CrI 
0.01-0.85 P(better)= 2%, 0.15 95%CrI 0- 8.74 P(better)= 16% respectively] even though 
the later techniques had an advantage over MYO due to shorter hospitalization 
and quicker recovery. There was no evidence of convincing difference between the 
three techniques in the number of women experiencing ovarian failure, minor or 
major complications. However, MYO may lead to better conception outcomes in 
absolute error was on average 0.15 but was considerably high (> 0.34) if the observed 
EQ-5D value was below 0.5. Sensitivity analysis revealed that different EQ-5D value 
sets resulted in different algorithms but similar predicting ability. cOnclusiOns: 
Our study showed that there are conceptual differences between the CCQ and EQ-5D 
and mapping should be considered as second-best option compared to directly 
collected EQ-5D data. Furthermore, the mapping performance seems to depend on 
the severity of the study population.
Ql2
mEaSuRing PatiEnt-RElEVant tREatmEnt bEnEfit in dERmatology – 
dEVEloPmEnt and Validation of tHE SHoRt QuEStionnaiRE “PatiEnt 
bEnEfit indEx 2.0”
Blome C.1, von Usslar K.1, Augustin M.2
1University Medical Center Hamburg, Hamburg, Germany, 2University Medical Center Hamburg-
Eppendorf, Hamburg, Germany
Objectives: Evidence on patient-relevant treatment benefit is the main criterion 
for reimbursement decisions in many European countries. Usually, an increase of 
quality of life (QoL) during treatment is used as benefit indicator. The Patient Benefit 
Index (PBI) method, in contrast, evaluates benefit retrospectively: Before treatment, 
patients rate importance of treatment goals; after treatment, they rate goal achieve-
ment. This prevents any bias due to response shift which has repeatedly been found 
in pre-post QoL assessment. Here, we developed a short PBI version (“PBI 2.0”) appli-
cable to different skin diseases. MethOds: Treatment goal items for the PBI 2.0 
were developed based on nine validated disease-specific PBI versions. Items were 
tested for content, completeness, and comprehensiveness in qualitative interviews 
with n= 16 patients with atopic dermatitis, leg ulcers, psoriasis, and vitiligo. Items 
were revised on basis of patient feedback. The PBI 2.0 was tested for convergent 
validity, completeness, and congruence with disease-specific PBI versions in a cross-
sectional study on n= 379 patients with the above-mentioned diagnoses. Results: 
The 74 disease-specific items could be condensed to 15 pilot items. Based on the 
qualitative interviews, we could reduce to 12 items. The majority of patients rated 
the PBI 2.0 to be comprehensible (93-98%, depending on diagnosis group), readable 
(94-100%), easy to answer throughout (78-90%), and complete (65-88%). Treatment 
goals mentioned as missing mostly concerned goals unrelated to benefit of medical 
treatment (e.g. information on the disease). The percentage of missing values ranged 
from 0.0% to 2.9%. PBI 2.0 preference-weighted global scores correlated significantly 
with QoL as measured with Dermatology Life Quality Index and EQ-5D (r= 0.19 to 
0.58). Convergent validity of the PBI 2.0 and the respective – about twice as long – 
disease-specific versions were equal, except for the vitiligo version. cOnclusiOns: 
The PBI 2.0 is a qualitatively and quantitatively validated short questionnaire on 
patient-relevant treatment benefit in dermatology.
Ql3
tHE mEaSuREmEnt of HEaltH-RElatEd Quality of lifE: gERman 
findingS fRom tHE multi-inStRumEnt comPaRiSon (mic) Study
Schlander M.1, Khan M.A.2, Iezzi A.2, Maxwell A.2, Richardson J.2
1University of Heidelberg, Wiesbaden, Germany, 2Monash University, Melbourne, Australia
Objectives: Different multi-attribute utility (MAU) instruments are known to pro-
duce different values for “utility” and measure different constructs, despite the 
common label “utility”. To date, the Multi-Instrument Comparison (MIC) project has 
been the largest comparative study of health and well-being instruments under-
taken worldwide. Here we report the first results from the German branch of the 
study. MethOds: A total of 1269 German respondents (either healthy or suffering 
from defined chronic disorders, i.e., asthma, arthritis, cancer, depression, diabetes, 
hearing loss, heart disease) were recruited and participated in the study, completing 
various MAU instruments, including the EQ-5D, SF-6D, HUI3, 15D, QWB, AQoL(-4D 
and-8D). Cross-validation tests drew heavily on correlation. Preliminary findings, 
based upon Pearson correlation coefficients (indicating the extent to which changes 
in one variable correspond with changes in another), showed low correlations 
between measures of utility and measures of subjective well-being. While prefer-
ences might differ from subjective well-being, their correlation might be higher. 
Hence, a better measure should be intraclass correlation (ICC). Results: Intraclass 
correlations between MAU instruments ranged from to 0.8 (HUI3 vs. AQoL-8D) to 
0.4 (AQoL-4D vs. 15D). Linear regression results, reflecting the comparative perfor-
mance of the various MAU instruments with regard to changes in measured utilities 
(as applied in standard cost utility analysis), and detailed results including pair-
wise comparisons of instruments, especially as to sensitivity to changes in a given 
dimension, will be presented. cOnclusiOns: A major conclusion of the present 
study is that, despite some similarity in the mean scores, the instruments tested are 
dissimilar with regard to virtually all other criteria used to compare them. In effect, 
each instrument appears to measure a different construct of “health”. Implications 
for the presumably “generic” measurement of “utility” may be far reaching and will 
be discussed.
Ql4
PSycHomEtRic Validation of PERcEiVEd dEficitS QuEStionnaiRE – 
dEPRESSion (PdQ-d) in PatiEntS witH majoR dEPRESSiVE diSoRdER (mdd)
Lam R.W.1, Saragoussi D.2, Danchenko N.3, Rive B.4, Lamy F.X.5, Brevig T.6
1University of British Columbia, Vancouver, BC, Canada, 2Lundbeck SAS, ISSY LES MOULINEAUX 
CEDEX, France, 3Lundbeck SAS, Issy-les-Moulineaux, France, 4Lundbeck S.A.S., Issy-Les 
Moulineaux, France, 5Lundbeck S.A.S., Issy-les-Moulineaux, France, 6H. Lundbeck A/S, Valby, 
Denmark
Objectives: The Perceived Deficits Questionnaire (PDQ) provides a self-report 
measure of cognitive dysfunction. The current work aims at assessing the psycho-
metric properties of the PDQ adapted for MDD (PDQ-D). MethOds: A non-inter-
ventional, online panel survey with baseline assessment and 6-week follow-up 
of US and UK residents (aged ≥ 18 years) with and without MDD [diagnosed with 
depression by a physician and current Patient Health Questionnaire-9 (PHQ-9) 
score ≥ 10]. In addition to PDQ-D, the following instruments were included: Medical 
